Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis

Background To measure circulating anti-citrullinated peptide antibodies (ACPA) and cytokines pre- and 6 months post-therapy as a strategy to predict and optimize responses to traditional disease-modifying antirheumatic drugs (DMARDs) in early RA, which is an unmet need in developing countries. Patients and methods A cohort of 140 predominantly (88.5 %) black female South African patients with early RA was treated with synthetic DMARDs, mostly methotrexate (MTX) alone, or in combination with low-dose oral corticosteroids (CS). Circulating ACPA and a panel of circulating cytokines/chemokines/growth factors were measured at baseline and after 6 months of therapy in relation to disease activity and Shared Epitope (SE). Results Following 6 months of therapy, the median simplified disease activity index (SDAI) declined from a baseline of 41.4 to 16.0 (p = 0.0001) for the entire cohort, which was paralleled by significant falls in median serum ACPA levels (516.6 vs. 255.7 units/ml, p = <0.0001) and several of the circulating cytokines (IL-4, IL-7, IL-8, G-CSF, VEGF; p < 0.0010 – p < 0.0001) which were most evident in the subgroup of patients treated with a combination of MTX and CS. Although biomarker concentrations decreased most notably in the low-disease activity group post-therapy, no significant correlations between these biomarkers and disease activity were observed, Baseline ACPA levels, but not SDAI or cytokines, were significantly higher in the subgroup of risk allele-positive patients (561.1 vs. 331.9 units/ml, p < 0.05), while no associations with ACPA and a smoking history were evident. Conclusions The use of DMARDs in RA is associated with significant decreases in ACPA and cytokines which did not correlate with changes in SDAI, precluding the utility of serial measurement of these biomarkers to monitor early responses to therapy, but may have prognostic value..

Medienart:

E-Artikel

Erscheinungsjahr:

2015

Erschienen:

2015

Enthalten in:

Zur Gesamtaufnahme - volume:16

Enthalten in:

BMC musculoskeletal disorders - 16(2015), 1 vom: 29. Mai

Sprache:

Englisch

Beteiligte Personen:

Ally, Mahmood M. T. M. [VerfasserIn]
Hodkinson, Bridget [VerfasserIn]
Meyer, Pieter W. A. [VerfasserIn]
Musenge, Eustasius [VerfasserIn]
Tintinger, Gregory R. [VerfasserIn]
Tikly, Mohammed [VerfasserIn]
Anderson, Ronald [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Anticyclic citrullinated peptide antibodies
Cytokines
Disease modifying antirheumatic drugs
Rheumatoid arthritis
Shared epitope

Anmerkungen:

© Ally et al.; licensee BioMed Central. 2015

doi:

10.1186/s12891-015-0587-1

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

OLC210068888X

Zugang & Verfügbarkeit




Zugehörige Publikationen/Bände

    Haven't found what you're looking for?